Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR105 in Relapsed Advanced Malignancies
NCT05605119Phase 1Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aur105 in solid tumor, non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Safety and Tolerability at 1 year, Pharmacokinetics at Day 16 and 1 more. Started Nov 2022; status: terminated.
02
Drugs
aur105
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05605119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605119.